V. Meta-Analysis of the Efficacy of Hormone Replacement Therapy in Treating and Preventing Osteoporosis in Postmenopausal Women

Objective: To review the effect of hormone replacement therapy (HRT) on bone density and fractures in postmenopausal women. Data Source: We searched MEDLINE and EMBASE from 1966 to 1999, the Cochrane Controlled Register, citations of relevant articles, and proceedings of international meetings for eligible randomized controlled trials. We contacted osteoporosis investigators to identify additional studies, and primary authors for unpublished data. Study Selection: We included 57 studies that randomized postmenopausal women to HRT or a control (placebo or calcium/vitamin D) and were of at least 1 yr in duration. Seven of these studies reported fractures. Data Abstraction: For each study, three independent reviewers assessed the methodological quality and abstracted the data. Data Synthesis: HRT showed a trend toward reduced incidence of vertebral fractures [relative risk (RR) 0.66, 95% confidence interval (CI) 0.41-1.07; 5 trials] and nonvertebral fractures (RR 0.87, 95% CI 0.71-1.08; 6 trials). HRT had a consistent effect on bone mineral density (BMD) at all sites. The difference between HRT and control in the percent change in bone density at 2 yr was 6.76 (5.83, 7.89; 21 trials) at the lumbar spine and 4.53 (3.68, 5.36; 14 trials) and 4.12 (3.45, 4.80; 9 trials) at the forearm and femoral neck, respectively. Conclusions: HRT has a consistent, favorable and large effect on bone density at all sites. The data show a nonsignificant trend toward a reduced incidence in vertebral and nonvertebral fractures.

[1]  D. Torgerson,et al.  Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials , 2001, BMC musculoskeletal disorders.

[2]  C. Viscoli,et al.  A clinical trial of estrogen-replacement therapy after ischemic stroke. , 2001, The New England journal of medicine.

[3]  S. Fowler,et al.  Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. , 2001, The Journal of clinical endocrinology and metabolism.

[4]  K. Schenck-Gustafsson,et al.  Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 2001, Circulation.

[5]  D. Torgerson,et al.  Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. , 2001, JAMA.

[6]  P. Vestergaard,et al.  Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. , 2000, Maturitas.

[7]  D. Reboussin,et al.  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000, The New England journal of medicine.

[8]  I. Reid,et al.  Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women. , 2000, Archives of internal medicine.

[9]  Anthony Gamst,et al.  Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial , 2000 .

[10]  L. Pottern,et al.  Commentary on the Women's Health Initiative. , 2000, Maturitas.

[11]  C. Coupland,et al.  Alendronate and EstrogenProgestin in the Long-Term Prevention of Bone Loss: Four-Year Results from the Early Postmenopausal Intervention Cohort Study: A Randomized, Controlled Trial , 1999, Annals of Internal Medicine.

[12]  S. Grundy,et al.  Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1999, Circulation.

[13]  S. Weiss,et al.  A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss , 1999 .

[14]  C. Christiansen,et al.  Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. , 1999, The Journal of clinical endocrinology and metabolism.

[15]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[16]  W. Gillespie,et al.  A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects. , 1998, Climacteric : the journal of the International Menopause Society.

[17]  S. Wimalawansa.  A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. , 1998, The American journal of medicine.

[18]  C. Christiansen,et al.  Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. , 1998 .

[19]  JoAnn E. Manson,et al.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.

[20]  E. Barrett-Connor,et al.  Hormone replacement therapy, heart disease, and other considerations. , 1998, Annual review of public health.

[21]  H. Genant,et al.  Low-Dose Esterified Estrogen Therapy: Effects on Bone, Plasma Estradiol Concentrations, Endometrium, and Lipid Levels , 1997 .

[22]  H. Genant,et al.  Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. , 1997, Archives of internal medicine.

[23]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[24]  A. Genazzani,et al.  Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women. , 1997, Maturitas.

[25]  P. Eiken,et al.  Effects on bone mass after eight years of hormonal replacement therapy , 1997, British journal of obstetrics and gynaecology.

[26]  C. Rosen,et al.  The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. , 1997, The Journal of clinical endocrinology and metabolism.

[27]  H. Mizunuma,et al.  Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study. , 1997, Maturitas.

[28]  S. Gonnelli,et al.  The Usefulness of Bone Turnover in Predicting the Response to Transdermal Estrogen Therapy in Postmenopausal Osteoporosis , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  J. Heikkinen,et al.  HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women. , 1997, Maturitas.

[30]  H. Beck-Nielsen,et al.  Cytokines and T-lymphocyte subsets in healthy post-menopausal women: estrogen retards bone loss without affecting the release of IL-1 or IL-1ra. , 1997, Bone.

[31]  T. M. Kashner,et al.  The Economic Cost of Hip Fractures in Community‐Dwelling Older Adults: A Prospective Study , 1997, Journal of the American Geriatrics Society.

[32]  H. Genant,et al.  The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. , 1996, JAMA.

[33]  I. Reid,et al.  Effect of Hormone Replacement Therapy on Bone Mineral Density in Postmenopausal Women with Mild Primary Hyperparathyroidism , 1996, Annals of Internal Medicine.

[34]  O. Johnell,et al.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures , 1996 .

[35]  H. Rico,et al.  Prophylaxis of osteoporosis with calcium, estrogens and/or eelcatonin: comparative longitudinal study of bone mass. , 1996, Maturitas.

[36]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[37]  M. Dören,et al.  Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. , 1995, American journal of obstetrics and gynecology.

[38]  S. Cummings,et al.  Estrogen Replacement Therapy and Fractures in Older Women , 1995, Annals of Internal Medicine.

[39]  S. Wimalawansa.  Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. , 1995, The American journal of medicine.

[40]  S. Boldrini,et al.  Cyclical clodronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  A. Genazzani,et al.  Prospective evaluation of calcium and estrogen administration on bone mass and metabolism after ovariectomy. , 1995, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[42]  S. Palacios,et al.  Effects of percutaneous oestradiol versus oral oestrogens on bone density. , 1994, Maturitas.

[43]  K. Dickersin,et al.  Systematic Reviews: Identifying relevant studies for systematic reviews , 1994 .

[44]  J. Aloia,et al.  Calcium Supplementation with and without Hormone Replacement Therapy To Prevent Postmenopausal Bone Loss , 1994, Annals of Internal Medicine.

[45]  Chuan Yi Tang,et al.  A 2.|E|-Bit Distributed Algorithm for the Directed Euler Trail Problem , 1993, Inf. Process. Lett..

[46]  J. Fleiss.  Review papers : The statistical basis of meta-analysis , 1993 .

[47]  J. L. Liu,et al.  Nylestriol replacement therapy in postmenopausal women. A three‐year prospective study , 1993, Chinese medical journal.

[48]  J. Pouilles,et al.  Effect of long‐term administration of progestogen on post‐menopausal bone loss: result of a two‐year, controlled randomized study , 1993 .

[49]  C. Castelo-Branco,et al.  Bone mineral density in surgically postmenopausal women receiving hormonal replacement therapy as assessed by dual photon absorptiometry. , 1993, Maturitas.

[50]  H. Genant,et al.  Low-Dosage Micronized 17β-Estradiol Prevents Bone Loss in Postmenopausal Women , 1992 .

[51]  A. Lane,et al.  Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen , 1992, Annals of Internal Medicine.

[52]  D. Kiel,et al.  Smoking Eliminates the Protective Effect of Oral Estrogens on the Risk for Hip Fracture among Women , 1992, Annals of Internal Medicine.

[53]  C. Castelo-Branco,et al.  The effect of hormone replacement therapy on postmenopausal bone loss. , 1992, European journal of obstetrics, gynecology, and reproductive biology.

[54]  H. Genant,et al.  Low-dosage micronized 17ß-estradiol prevents bone loss inpostmenopausal women , 1992 .

[55]  C. Christiansen,et al.  Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: Long‐term effects on bone, calcium and lipid metabolism, climacteric symptoms and bleeding , 1992, Obstetrics and gynecology.

[56]  B. Riis,et al.  Desogestrel in hormone replacement therapy: long‐term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding , 1991 .

[57]  H. Genant,et al.  The effects of estrone (Ogen) on spinal bone density of postmenopausal women. , 1991, Archives of internal medicine.

[58]  P. Fioretti,et al.  Neuroendocrine and clinical effects of transdermal 17 beta-estradiol in postmenopausal women. , 1991, Maturitas.

[59]  P. Geusens,et al.  Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. , 1991, Maturitas.

[60]  J. Gallagher,et al.  Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. , 1991, The American journal of medicine.

[61]  C. Christiansen,et al.  17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. , 1990, The Journal of clinical endocrinology and metabolism.

[62]  R. Civitelli,et al.  Calcitonin and estrogens , 1990, Journal of endocrinological investigation.

[63]  R. Lindsay,et al.  Estrogen treatment of patients with established postmenopausal osteoporosis , 1990, Obstetrics and gynecology.

[64]  H. Adami,et al.  Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. , 1990, Annals of internal medicine.

[65]  P. Pietschmann,et al.  Effects of one-year hormone replacement therapy on peripheral bone mineral content in patients with osteoporotic spine fractures. , 1990, Acta endocrinologica.

[66]  C. Campagnoli,et al.  Calcitonin and lumbar bone mineral content during oestrogen-progestogen administration in post-menopausal women. , 1989, Maturitas.

[67]  S. Adami,et al.  Transdermal estradiol in the treatment of postmenopausal bone loss. , 1989, Bone and mineral.

[68]  C. Christiansen,et al.  Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women. , 1988, Maturitas.

[69]  S. Wimalawansa,et al.  CALCITONIN FOR PREVENTION OF POSTMENOPAUSAL BONE LOSS , 1988, The Lancet.

[70]  S. P. Nielsen,et al.  Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double blind placebo controlled study , 1988, British medical journal.

[71]  C. Christiansen,et al.  Does calcium potentiate the effect of estrogen therapy on postmenopausal bone loss? , 1987, Bone and mineral.

[72]  C. Christiansen,et al.  Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. , 1987, The New England journal of medicine.

[73]  R. Lindsay,et al.  The Minimum Effective Dose of Estrogen for Prevention of Postmenopausal Bone Loss , 1984, Obstetrics and gynecology.

[74]  C. Christiansen,et al.  Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions. , 1982, American journal of obstetrics and gynecology.

[75]  H. Genant,et al.  Quantitative Computed Tomography of Vertebral Spongiosa: A Sensitive Method for Detecting Early Bone Loss After Oophorectomy , 1982, Annals of internal medicine.

[76]  C. Christiansen,et al.  TREATMENT OF POST MENOPAUSAL OSTEOPOROSIS. A CONTROLLED THERAPEUTIC TRIAL COMPARING OESTROGEN/GESTAGEN, 1,25‐DIHYDROXY‐VITAMIN D3 AND CALCIUM , 1982, Clinical endocrinology.

[77]  C. Christiansen,et al.  Effect of 1,25‐dihydroxy ‐ vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis , 1981, European journal of clinical investigation.

[78]  R. Lindsay,et al.  PREVENTION OF SPINAL OSTEOPOROSIS IN OOPHORECTOMISED WOMEN , 1980, The Lancet.

[79]  R. Lindsay,et al.  Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. , 1980, British medical journal.

[80]  L. Nachtigall,et al.  Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis. , 1979 .

[81]  R. Lindsay,et al.  Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. , 1978, Clinical science and molecular medicine.

[82]  R. Recker,et al.  Effect of estrogens and calcium carbonate on bone loss in postmenopausal women. , 1977, Annals of internal medicine.

[83]  A. Horsman,et al.  Prospective trial of oestrogen and calcium in postmenopausal women. , 1977, British medical journal.

[84]  R. Lindsay,et al.  LONG-TERM PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS BY ŒSTROGEN EVIDENCE FOR AN INCREASED BONE MASS AFTER DELAYED ONSET OF ŒSTROGEN TREATMENT , 1976, The Lancet.

[85]  R. Lindsay,et al.  Oestrogen Replacement Therapy for Prevention of Osteoporosis after Oophorectomy , 1973, British medical journal.

[86]  R. Salama.  MYELOMATOUS OSTEOSCLEROSIS AND PERIPHERAL NEUROPATHY. , 1965, Lancet.

[87]  Debono Ef.  OUTPATIENT WAITING TIME. , 1963 .